Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044031 | 0.97 | HPGD (0.57) | HPGDALDH1A1GAATSHRTDP1 | |
| SCHEMBL2482695 | 0.95 | HPGD (0.56) | HPGDALDH1A1GAATSHR | |
| SCHEMBL30317186 | 0.95 | HPGD (0.56) | HPGDALDH1A1GAATSHR | |
| SCHEMBL2206424 | 0.92 | TP53 (0.53) | HPGDALDH1A1BACE1TP53TDP1 | |
| Hydrochloric Acid SCHEMBL5037688 | 0.91 | TP53 (0.51) | HPGDALDH1A1BACE1TP53TDP1 | |
| SCHEMBL10724585 | 0.89 | HPGD (0.61) | HPGDALDH1A1GAATSHRTDP1 | |
| SCHEMBL10722469 | 0.86 | HPGD (0.69) | HPGDALDH1A1GAATP53TSHR | |
| SCHEMBL9361376 | 0.86 | TP53 (0.60) | HPGDALDH1A1BACE1TP53TSHR | |
| SCHEMBL18766848 | 0.85 | MLYCD (0.48) | HPGDALDH1A1GAABACE1TP53 | |
| SCHEMBL570949 | 0.84 | HPGD (0.56) | HPGDALDH1A1GAATSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345082-B2 | Phosphinic acids | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1685142-B1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20050107341-A1 | Phosphinic acids | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107341-A1 | Phosphinic acids | BACE1, PSEN1, PSEN2 | HPGD 2689/4885ALDH1A1 1510/4885GAA 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.